Cited by 522Colorectal Cancer Treatments and StudiesMonoclonal and Polyclonal Antibodies ResearchLung Cancer Treatments and Mutations

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan

Bibeau, Frédéric, Lopez-Crapez, Evelyne, Di Fiore, Frédéric, Thezenas, Simon, Ychou, Marc, Blanchard, France, Lamy, Aude, Penault-Llorca, Frédérique, Frébourg, Thierry, Michel, Pierre, Sabourin, Jean-Christophe, Boissière-Michot, Florence·2009·Journal of Clinical Oncology

DOI 10.1200/jco.2008.18.0463

Open this paper in CoChat — free account

Abstract

Purpose: The antiepidermal growth factor receptor antibody cetuximab shows activity in irinotecan-refractory metastatic colorectal cancer (mCRC), mainly in wild-type KRAS tumors. Cetuximab may also exert antitumor effects through antibody-dependent cell-mediated cytotoxicity (ADCC) in which antibody Fc portion interacts with Fc receptors (FcγRs) expressed by immune cells. ADCC is influenced by FcγRIIa-H131R and FcγRIIIa-V158F polymorphisms that are clinically relevant in follicular lymphoma and metastatic breast cancer treated with rituximab and trastuzumab, respectively. We investigated the association of FcγR polymorphisms and KRAS mutation with the outcome of irinotecan-refractory mCRC patients treated with cetuximab plus irinotecan. Patients and Methods: Tumor and normal tissues from 69 patients were screened for KRAS mutations using a sensitive multiplex assay and genotyped for FcγRIIa and FcγRIIIa polymorphisms by direct sequencing and multiplex allele-specific polymerase chain reaction, respectively. The results were correlated with response and progression-free survival (PFS). Results: KRAS mutations were associated with lower response rate (4% v 27% in nonmutated patients; P = .021) and shorter PFS (3.0 v 5.3 months; P = .021). Patients with FcγRIIa-131H/H and/or FcγIIIa-158V/V genotypes had longer PFS than 131R and 158F carriers (5.5 v 3.0 months; P = .005). The difference remained significant for mutated-KRAS patients. By multivariate analysis, KRAS mutation and FcγR combined status were independent risk factors for PFS. Conclusion: Combined FcγRIIa/FcγRIIIa polymorphisms are prognostic factors for disease progression in mCRC patients treated with cetuximab plus irinotecan. As these polymorphisms are also clinically relevant in mutated-KRAS mCRC, an important role of ADCC in cetuximab efficacy is presumed.

Integrity signals

Registry

Crossref · 10.1200/jco.2008.18.0463

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Self-citation
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
Cartron, G., Dacheux, L., Salles, G. A., Solal‐Céligny, P., BARDOS, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,954
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
Lièvre, A., Bachet, J., Boige, V., Cayre, A., Corre, D. L., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,485
Self-citation
Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma
Weng, W., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,324
Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab
Khambata-Ford, S., Garrett, C. R., Meropol, N. J., Basik, M., Harbison, C. T., Wu, S., Wong, T. W., Huang, X., Takimoto, C. H., Godwin, A. K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5437 · Cited by 1,125

Flagged first, then by citations

Show all 44 references

Research works printed but not linked: 2

Van Cutsem E, 2007, J Clin Oncol, 25, 164s
Kang X, 2007, J Clin Oncol, 25, 128s

Sorted by citations

Antibody therapy of cancer
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3236 · Cited by 2,244
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citation
Macrophages as tools and targets in cancer therapy
Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature reviews. Immunology · doi:10.1038/nri2744 · Cited by 1,339
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity
Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C. A., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 983
Monoclonal Antibodies in Cancer Therapy
Zahavi, D. J., & Weiner, L. M. (2020) · Antibodies · doi:10.3390/antib9030034 · Cited by 905
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
Thierry, A. R., Mouliere, F. C., Messaoudi, S. E., Mollévi, C., Lopez‐Crapez, E., Rolet, F., Gillet, B., Gongora, C., Dechelotte, P., Robert, B., et al. (2014) · Nature Medicine · doi:10.1038/nm.3511 · Cited by 687
Self-citation
The secret ally: immunostimulation by anticancer drugs
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 708
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wang, W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00368 · Cited by 623
Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer
Siena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Balfour, J., & Bardelli, A. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp280 · Cited by 429
Type I and type II Fc receptors regulate innate and adaptive immunity
Pincetic, A., Bournazos, S., DiLillo, D. J., Maamary, J., Wang, T. T., Dahan, R., Fiebiger, B. M., & Ravetch, J. V. (2014) · Nature Immunology · doi:10.1038/ni.2939 · Cited by 517
Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin
Maubec, E., Petrow, P. K., Scheer-Senyarich, I., Duvillard, P., Lacroix, L., Gelly, J., Certain, A., Duval, X., Crickx, B., Buffard, V., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1735 · Cited by 469
Targeting the ERBB family in cancer: couples therapy
Tebbutt, N. C., Pedersen, M. W., & Johns, T. G. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3559 · Cited by 464
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
Normanno, N., Tejpar, S., Morgillo, F., De Luca, A., Van Cutsem, E., & Ciardiello, F. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.111 · Cited by 436
Immunotherapy of cancer in 2012
Kirkwood, J. M., Butterfield, L. H., Tarhini, A. A., Zarour, H. M., Kaliński, P., & Ferrone, S. (2012) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20132 · Cited by 450
Antibody Glycosylation and Its Impact on the Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies and Fc-Fusion Proteins
Liu, L. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24444 · Cited by 428
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
Mellor, J. D., Brown, M. P., Irving, H. R., Zalcberg, J. R., & Dobrovic, A. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-1 · Cited by 417
Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells
Klingemann, H., Boissel, L., & Toneguzzo, F. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00091 · Cited by 422
Fc glycans of therapeutic antibodies as critical quality attributes
Reusch, D., & Tejada, M. L. (2015) · Glycobiology · doi:10.1093/glycob/cwv065 · Cited by 421
IgG Fc engineering to modulate antibody effector functions
Wang, X., Mathieu, M., & Brezski, R. J. (2018) · Protein & Cell · doi:10.1007/s13238-017-0473-8 · Cited by 356
Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond
Hogarth, P. M., & Pietersz, G. A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd2909 · Cited by 358
Advancement and applications of peptide phage display technology in biomedical science
Wu, C., Liu, I.-J., Lu, R., & Wu, H. (2016) · Journal of Biomedical Science · doi:10.1186/s12929-016-0223-x · Cited by 343
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape
Ferris, R. L., Jaffee, E. M., & Ferrone, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6360 · Cited by 320
Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Srivastava, R. M., Lee, S. C., Filho, P. A. A., Lord, C. A., Jie, H.-B., Davidson, H. C., López‐Albaitero, A., Gibson, S. P., Gooding, W. E., Ferrone, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2426 · Cited by 321
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
Janne, P. A., Gray, N. S., & Settleman, J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2871 · Cited by 312
The immune system and response to HER2-targeted treatment in breast cancer
Bianchini, G., & Gianni, L. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70477-7 · Cited by 287
Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity
Loo, D. T., Alderson, R. F., Chen, F. Z., Huang, L., Zhang, W., Gorlatov, S. N., Burke, S., Ciccarone, V. C., Li, H., Yang, Y., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0715 · Cited by 285
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
Kohrt, H. E. K., Thielens, A., Marabelle, A., Sagiv-Barfi, I., Sola, C., Chanuc, F., Fuséri, N., Bonnafous, C., Czerwinski, D. K., Rajapaksa, A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-519199 · Cited by 293
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
Apétoh, L., Ladoire, S., Coukos, G., & Ghiringhelli, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv209 · Cited by 286
Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity
Huang, Z., Blum, R. H., Bjordahl, R., Gaidarova, S., Rogers, P., Lee, T. T., Abujarour, R., Bonello, G. B., Wu, J., Tsai, P.-F., et al. (2019) · Blood · doi:10.1182/blood.2019000621 · Cited by 282
Macrophages eliminate circulating tumor cells after monoclonal antibody therapy
Gül, N., Babes, L., Siegmund, K., Korthouwer, R., Bögels, M., Braster, R., Vidarsson, G., ten Hagen, T. L. M., Kubes, P., & van Egmond, M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci66776 · Cited by 283
Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties
Nordstrom, J. L., Gorlatov, S. N., Zhang, W., Yang, Y., Huang, L., Burke, S., Li, H., Ciccarone, V. C., Zhāng, T., Stavenhagen, J. B., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr3069 · Cited by 257
An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
Wilson, N. S., Yang, B., Yang, A., Loeser, S., Marsters, S. A., Lawrence, D. A., Li, Y., Pitti, R. M., Tótpál, K., Yee, S. F., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.012 · Cited by 247
Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies
Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246
Natural Killer Cell Mediated Antibody-Dependent Cellular Cytotoxicity in Tumor Immunotherapy with Therapeutic Antibodies
Seidel, U. J. E., Schlegel, P., & Lang, P. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00076 · Cited by 244
KRAS mutation testing in metastatic colorectal cancer.
Tan, C., & Du, X. (2012) · PubMed · doi:10.3748/wjg.v18.i37.5171 · Cited by 238
Signaling by Antibodies: Recent Progress
Bournazos, S., Wang, T. T., Dahan, R., Maamary, J., & Ravetch, J. V. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052433 · Cited by 230
CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes
Yeap, W. H., Wong, K. L., Shimasaki, N., Teo, E. C. Y., Quek, J. K. S., Yong, H. X., Diong, C. P., Bertoletti, A., Linn, Y. C., & Wong, S. C. (2016) · Scientific Reports · doi:10.1038/srep34310 · Cited by 230
Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody
White, A. L., Chan, H. T. C., Roghanian, A., French, R. R., Mockridge, C. I., Tutt, A. L., Dixon, S. V., Ajona, D., Verbeek, J. S., Al‐Shamkhani, A., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101135 · Cited by 227
Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage
Schneider‐Merck, T., van Bueren, J. J. L., Berger, S., Rossen, K., van Berkel, P. H. C., Derer, S., Beyer, T. D., Lohse, S., Bleeker, W. K., Peipp, M., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900847 · Cited by 223
Tumor-associated myeloid cells: diversity and therapeutic targeting
Mantovani, A., Marchesi, F., Jaillon, S., Garlanda, C., & Allavena, P. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00613-4 · Cited by 230
Natural Killer Cells in Human Cancer: From Biological Functions to Clinical Applications
Levy, E. M., Roberti, M. P., & Mordoh, J. (2011) · BioMed Research International · doi:10.1155/2011/676198 · Cited by 218
Anti–Tumor Necrosis Factor-α Antibodies Induce Regulatory Macrophages in an Fc Region-Dependent Manner
Vos, A. C. W., Wildenberg, M. E., Duijvestein, M., Verhaar, A. P., BRINK, G. R. V. D., & Hommes, D. W. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.10.008 · Cited by 218
Antibody-Dependent Phagocytosis of Tumor Cells by Macrophages: A Potent Effector Mechanism of Monoclonal Antibody Therapy of Cancer
Gül, N., & van Egmond, M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1330 · Cited by 212
Tricking the balance: NK cells in anti-cancer immunity
Pahl, J. H. W., & Cerwenka, A. (2015) · Immunobiology · doi:10.1016/j.imbio.2015.07.012 · Cited by 207
T Lymphocytes Expressing a CD16 Signaling Receptor Exert Antibody-Dependent Cancer Cell Killing
Kudo, K., Imai, C., Lorenzini, P. A., Kamiya, T., Kono, K., Davidoff, A. M., Chng, W. J., & Campana, D. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1365 · Cited by 190
Fcγ Receptor Function and the Design of Vaccination Strategies
Bournazos, S., & Ravetch, J. V. (2017) · Immunity · doi:10.1016/j.immuni.2017.07.009 · Cited by 188
FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer
Tamura, K., Shimizu, C., Hojo, T., Akashi‐Tanaka, S., Kinoshita, T., Yonemori, K., Kouno, T., Katsumata, N., Ando, M., Aogi, K., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq585 · Cited by 192
An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele
Jochéms, C., Hodge, J. W., Fantini, M. C., Fujii, R., Morillon, Y. M., Greiner, J. W., Padget, M. R., Tritsch, S. R., Tsang, K. Y., Campbell, K. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13411 · Cited by 182
Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies
Thomann, M., Reckermann, K., Reusch, D., Prasser, J., & Tejada, M. L. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.03.002 · Cited by 179
Monoclonal antibodies in the treatment of metastatic colorectal cancer: A review
Tol, J., & Punt, C. J. A. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.03.012 · Cited by 178
Monoclonal antibodies for the treatment of cancer
Shuptrine, C. W., Surana, R., & Weiner, L. M. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.009 · Cited by 177
Systematic Review: Anti–Epidermal Growth Factor Receptor Treatment Effect Modification by KRAS Mutations in Advanced Colorectal Cancer
Dahabreh, I. J., Terasawa, T., Castaldi, P. J., & Trikalinos, T. A. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-1-201101040-00006 · Cited by 174
Use of Allogeneic NK Cells for Cancer Immunotherapy
Geller, M. A., & Miller, J. S. (2011) · Immunotherapy · doi:10.2217/imt.11.131 · Cited by 163
Targeting CD137 enhances the efficacy of cetuximab
Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73014 · Cited by 160
Retracted
Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy
Almagro, J. C., Daniels‐Wells, T. R., Pérez‐Tapia, S. M., & Penichet, M. L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01751 · Cited by 165
Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo
Cheung, N. V., Guo, H.-F., Hu, J., Tassev, D. V., & Cheung, I. Y. (2012) · OncoImmunology · doi:10.4161/onci.19864 · Cited by 157
Cleavage of IgGs by proteases associated with invasive diseases
Brezski, R. J., & Jordan, R. E. (2010) · mAbs · doi:10.4161/mabs.2.3.11780 · Cited by 159
Genomics and emerging biomarkers for immunotherapy of colorectal cancer
Kather, J. N., Halama, N., & Jaeger, D. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.010 · Cited by 154
The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies
Gogesch, P., Dudek, S., van Zandbergen, G., Waibler, Z., & Anzaghe, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168947 · Cited by 166
Fcγ receptor pathways during active and passive immunization
Bournazos, S., & Ravetch, J. V. (2015) · Immunological Reviews · doi:10.1111/imr.12343 · Cited by 151
The Human FcγRII (CD32) Family of Leukocyte FcR in Health and Disease
Anania, J. C., Chenoweth, A. M., Wines, B. D., & Hogarth, P. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00464 · Cited by 146
iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting
Goldenson, B. H., Hor, P., & Kaufman, D. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.841107 · Cited by 154
Boosting therapeutic potency of antibodies by taming Fc domain functions
Kang, T. H., & Jung, S. T. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0345-9 · Cited by 153
Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance
Krumbach, R., Schüler, J. B., Hofmann, M., Giesemann, T., Fiebig, H., & Beckers, T. L. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.12.019 · Cited by 142
CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells
Pahl, J. H. W., Koch, J., Götz, J.-J., Arnold, A., Reusch, U., Gantke, T., Rajkovic, E., Treder, M., & Cerwenka, A. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0550 · Cited by 137
89Zr-cetuximab PET imaging in patients with advanced colorectal cancer
van Oordt, C. W. M. D. H., Gootjes, E. C., Huisman, M. C., Vugts, D. J., Roth, C., Luik, A. M., Mulder, E. R., Schuit, R. C., Boellaard, R., Hoekstra, O. S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4672 · Cited by 134
SK3/TRPC1/Orai1 complex regulates SOCE-dependent colon cancer cell migration: a novel opportunity to modulate anti-EGFR mAb action by the alkyl-lipid Ohmline
Guéguinou, M., Harnois, T., Crottès, D., Uguen, A., Déliot, N., Gambade, A., Chantôme, A., Haelters, J. P., Jaffrès, P. A., Jourdan, M. L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8786 · Cited by 144
Therapeutic monoclonal antibody N-glycosylation – Structure, function and therapeutic potential
Cymer, F., Beck, H., Rohde, A., & Reusch, D. (2017) · Biologicals · doi:10.1016/j.biologicals.2017.11.001 · Cited by 142
A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy
Zhang, W., Winder, T., Ning, Y., Pohl, A. C., Yang, D., Kahn, M. R., Lurje, G., LaBonte, M. J., Wilson, P. M., Gordon, M. A., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq315 · Cited by 138
Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients
Trivedi, S., Srivastava, R. M., Concha‐Benavente, F., Ferrone, S., García-Bates, T. M., Li, J., & Ferris, R. L. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2971 · Cited by 133
Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions
DiLillo, D. J., & Ravetch, J. V. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0120 · Cited by 132
Neutrophils as effector cells for antibody-based immunotherapy of cancer
van Egmond, M., & Bakema, J. E. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.12.002 · Cited by 134
Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy
Zahavi, D. J., Aldeghaither, D. S., O’Connell, A., & Weiner, L. M. (2018) · Antibody Therapeutics · doi:10.1093/abt/tby002 · Cited by 135
Complement in monoclonal antibody therapy of cancer
Rogers, L. M., Veeramani, S., & Weiner, G. J. (2014) · Immunologic Research · doi:10.1007/s12026-014-8542-z · Cited by 128
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck
Sharafinski, M. E., Ferris, R. L., Ferrone, S., & Grandis, J. R. (2010) · Head & Neck · doi:10.1002/hed.21365 · Cited by 127
EGFR and KRAS in Colorectal Cancer
Markman, B., Ramos, F. J., Capdevila, J., & Tabernero, J. M. (2010) · Advances in clinical chemistry · doi:10.1016/s0065-2423(10)51004-7 · Cited by 130
Antibody Glycosylation and Inflammation
Shade, K.-T., & Anthony, R. M. (2013) · Antibodies · doi:10.3390/antib2030392 · Cited by 129
Treatment of Unresectable and Metastatic Cutaneous Squamous Cell Carcinoma
Cranmer, L. D., Engelhardt, C., & Morgan, S. S. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0210 · Cited by 125
GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab
Gerdes, C. A., Nicolini, V., Herter, S., van Puijenbroek, E., Lang, S., Roemmele, M., Moessner, E., Freytag, O., Friess, T., Ries, C. H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0989 · Cited by 123
IgA EGFR antibodies mediate tumour killing in vivo
Boross, P., Lohse, S., Nederend, M., Jansen, J. H. M., van Tetering, G., Dechant, M., Peipp, M., Royle, L., Liew, L. P., Boon, L., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201929 · Cited by 118
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients
Hurvitz, S. A., Betting, D. J., Stern, H. M., Quinaux, E., Stinson, J., Seshagiri, S., Zhao, Y., Buyse, M., Mackey, J., Driga, A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2294 · Cited by 115
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer
Gavin, P. G., Song, N., Kim, S. R., Lipchik, C., Johnson, N. L., Bandos, H., Finnigan, M., Rastogi, P., Fehrenbacher, L., Mamounas, E. P., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4884 · Cited by 115
Tumor-Associated Macrophages Promote Invasion while Retaining Fc-Dependent Anti-Tumor Function
Grugan, K. D., McCabe, F. L., Kinder, M., Greenplate, A. R., Harman, B. C., Ekert, J. E., van Rooijen, N., Anderson, G. M., Nemeth, J. A., Strohl, W. R., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201889 · Cited by 111
Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia
Ågerstam, H., Karlsson, C., Hansen, N., Sandén, C., Askmyr, M., von Palffy, S., Högberg, C., Rissler, M., Wunderlich, M., Juliusson, G., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1422749112 · Cited by 111
Single-cell genomic approaches for developing the next generation of immunotherapies
Yofe, I., Dahan, R., & Amit, I. (2020) · Nature Medicine · doi:10.1038/s41591-019-0736-4 · Cited by 107
Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma
Pahl, J. H. W., Ruslan, S. E. N., Buddingh, E. P., Santos, S. J., Szuhai, K., Serra, M., Gelderblom, H. A. J., Hogendoorn, P. C. W., Egeler, R. M., Schilham, M. W., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2277 · Cited by 111
Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients
Azzopardi, N., Lecomte, T., Ternant, D., Boisdron-Celle, M., Piller, F., Morel, A., Gouilleux‐Gruart, V., Desvignes, C., Watier, H., Gamelin, E. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1081 · Cited by 110
Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy
Leconet, W., Larbouret, C., Chardès, T., Thomas, G., Neiveyans, M., Busson, M., Jarlier, M., Radosevic‐Robin, N., Pugnière, M., Bernex, F., et al. (2013) · Oncogene · doi:10.1038/onc.2013.487 · Cited by 107
Self-citation
Nucleolin-based targeting strategies for cancer therapy: from targeted drug delivery to cytotoxic ligands
Romano, S., Fonseca, N. A., Simões, S., Gonçalves, J., & Moreira, J. N. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.018 · Cited by 104
Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
Manceau, G., Imbeaud, S., Thiébaut, R., Liébaert, F., Fontaine, K., Rousseau, F., Génin, B., Corre, D. L., Didelot, A., Vincent, M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2750 · Cited by 105
Self-citation
RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation
Mirschberger, C., Schiller, C., Schräml, M., Dimoudis, N., Friess, T., Gerdes, C. A., Reiff, U., Lifke, V., Hoelzlwimmer, G., Kolm, I., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0099 · Cited by 103
Taming the dragon: genomic biomarkers to individualize the treatment of cancer
Majewski, I. J., & Bernards, R. (2011) · Nature Medicine · doi:10.1038/nm.2311 · Cited by 101
Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab
Pander, J., Heusinkveld, M., van der Straaten, T., Jordanova, E. S., Baak-Pablo, R., Gelderblom, H., Morreau, H., van der Burg, S. H., Guchelaar, H.-J., & van Hall, T. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0239 · Cited by 101
Fcγ receptors: genetic variation, function, and disease
Hargreaves, C. E., Rose-Zerilli, M. J. J., Machado, L. R., Iriyama, C., Hollox, E. J., Cragg, M. S., & Strefford, J. C. (2015) · Immunological Reviews · doi:10.1111/imr.12341 · Cited by 104
Combination Strategies to Enhance Antitumor ADCC
Kohrt, H. E. K., Houot, R., Marabelle, A., Cho, H. J., Osman, K., Goldstein, M. J., Levy, R., & Brody, J. (2012) · Immunotherapy · doi:10.2217/imt.12.38 · Cited by 102
Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
Park, J., Kim, S.-E., Keam, B., Park, H.-R., Kim, S., Kim, M., Kim, T. M., Doh, J., Kim, D., & Heo, D. S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000873 · Cited by 97
Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: Beyond KRAS mutations
Custodio, A., & Feliú, J. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.05.001 · Cited by 100
Genetic Variation in Low-To-Medium-Affinity Fcγ Receptors: Functional Consequences, Disease Associations, and Opportunities for Personalized Medicine
Nagelkerke, S. Q., Schmidt, D. E., de Haas, M., & Kuijpers, T. W. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02237 · Cited by 94
Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells
Dixon, K. J., Wu, J., & Walcheck, B. K. (2021) · Cancers · doi:10.3390/cancers13020312 · Cited by 94

Authors: Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., Sabourin, J.-C., & Boissière-Michot, F.
Affiliations: Inserm (FR)
From the Departments of Pathology, Biology, Biostatistics, and Oncology, Centre Régional de Lutte Contre le Cancer Val d'Aurelle-Paul Lamarque, Montpellier; Digestive Oncology Unit, Department of Gastroenterology, Rouen University Hospital; Inserm U614, Faculty of Medicine; Department of Pathology, Rouen University Hospital; and the Department of Pathology, Centre Jean Perrin, Clermont-Ferrand, France.
ORCID: Bibeau, Frédéric
Ychou, Marc
Frébourg, Thierry
Michel, Pierre
Sabourin, Jean-Christophe
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2009-03-01
Volume: 27
Issue: 7
Pages: 1122-1129
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2008.18.0463
OpenAlex: W2122618533
Cited by: 521
References: 44
Citations by year: 2026: 3 · 2025: 13 · 2024: 12 · 2023: 19 · 2022: 16 · 2021: 17 · 2020: 24 · 2019: 16 · 2018: 26 · 2017: 24 · 2016: 32 · 2015: 40 · 2014: 41 · 2013: 46 · 2012: 53
FWCI: 31.59
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords: FcγRIIIa, Fc receptor polymorphism, KRAS mutation, cetuximab, irinotecan, metastatic colorectal cancer, antibody-dependent cellular cytotoxicity, progression-free survival, prognostic factors, irinotecan-refractory disease, epidermal growth factor receptor
MeSH terms: Cetuximab, Irinotecan, Antibodies, Monoclonal, Antibody-Dependent Cell Cytotoxicity, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Female, Humans, Male, Middle Aged, Mutation, Polymorphism, Genetic, Proto-Oncogene Proteins, Retrospective Studies, Colorectal Neoplasms, Multivariate Analysis, Proportional Hazards Models, Survival Analysis, Proto-Oncogene Proteins p21(ras), Receptors, IgG, Disease-Free Survival, ras Proteins, Drug Resistance, Neoplasm, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks